Global Autoinjector Market to Reach USD 8.2 Billion by 2033, Propelled by Growing Prevalence of Chronic Diseases

December 31, 2024 | Healthcare

The latest report by IMARC Group, titled “Autoinjector Market Report by Type (Disposable Autoinjectors, Reusable Autoinjectors), Application (Rheumatoid Arthritis, Anaphylaxis, Multiple Sclerosis, and Others), End User (Home Care Settings, Hospitals and Clinics), and Region 2025-2033,” finds that the global autoinjector market reached a value of USD 2.6 Billion in 2024. An autoinjector is a self-injectable device having a pre-charged dosage of drugs. It delivers drugs through the subcutaneous or intramuscular route and offers several advantages, such as dosage accuracy, improved patient compliance, lower needlestick injuries, and enhanced efficiency of healthcare professionals. These devices are widely used during emergency conditions, such as migraine, anaphylaxis, status epilepticus, diabetes, psoriasis, multiple sclerosis, and rheumatoid arthritis. Owing to these properties, autoinjectors find extensive applications in hospitals, clinics, and home care centers across the globe.

Global Autoinjector Market Trends:

The market is primarily driven by the growing prevalence of asthma, arthritis, cancer, chronic obstructive pulmonary disease (COPD), and Alzheimer’s disease. In addition, the implementation of favorable government initiatives to promote the use of autoinjectors in schools represents another major growth-inducing factor. Besides this, key players are investing in research and development (R&D) activities to develop cost-effective and new technology-based autoinjectors for treating rheumatoid arthritis and multiple sclerosis. This, coupled with the rising awareness among individuals about the benefits of autoinjectors, is contributing to market growth. Moreover, the growing adoption of targeted therapies to alter proteins within cancer cells and prevent the formation of blood vessels in the tumor is also creating a favorable market outlook across the globe. Looking forward, IMARC Group expects the market to reach a value of USD 8.2 Billion by 2033, exhibiting a CAGR of 13.19% during 2025-2033.

Market Summary:

  • Based on the type, the market has been categorized into disposable and reusable autoinjectors.
  • On the basis of the application, the market has been segregated into rheumatoid arthritis, anaphylaxis, multiple sclerosis, and others.
  • Based on the end user, the market has been bifurcated into home care settings, and hospitals and clinics.
  • Region-wise, the market has been divided into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
  • The competitive landscape of the market has been examined in the report, with some of the key players being Amgen Inc., Antares Pharma Inc., Becton Dickinson and Company, Bristol-Myers Squibb Company, Eisai Co. Ltd., Eli Lilly and Company, Haselmeier GmbH (Sulzer Ltd.), Johnson & Johnson, Mylan N.V. (Viatris Inc.), Novartis AG, SHL Medical AG, Teva Pharmaceutical Industries Ltd., and Ypsomed Holding AG.


Report Coverage:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Type, Application, End User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Amgen Inc., Antares Pharma Inc., Becton Dickinson and Company, Bristol-Myers Squibb Company, Eisai Co. Ltd., Eli Lilly and Company, Haselmeier GmbH (Sulzer Ltd.), Johnson & Johnson, Mylan N.V. (Viatris Inc.), Novartis AG, SHL Medical AG, Teva Pharmaceutical Industries Ltd. and Ypsomed Holding AG.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St, Ste 
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Autoinjector Market to Reach USD 8.2 Billion by 2033, Propelled by Growing Prevalence of Chronic Diseases
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials